Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. trimmed its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 19.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,258 shares of the biopharmaceutical company’s stock after selling 1,788 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Celldex Therapeutics were worth $269,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Celldex Therapeutics by 16.3% in the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after purchasing an additional 427,827 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of Celldex Therapeutics by 105.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after buying an additional 1,413,722 shares during the period. Affinity Asset Advisors LLC lifted its stake in Celldex Therapeutics by 166.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $15,864,000 after acquiring an additional 250,000 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after acquiring an additional 47,844 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after acquiring an additional 2,664,915 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CLDX. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Monday, August 12th. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday. Finally, Wells Fargo & Company boosted their target price on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $63.83.

Celldex Therapeutics Trading Down 1.6 %

Celldex Therapeutics stock opened at $41.16 on Friday. The company has a fifty day simple moving average of $38.51 and a 200-day simple moving average of $38.80. The stock has a market cap of $2.71 billion, a P/E ratio of -14.44 and a beta of 1.56. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. As a group, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.